Avalo Therapeutics (AVTX) Accumulated Depreciation (2014 - 2015)
Avalo Therapeutics' (AVTX) quarterly Accumulated Depreciation came in at $60835.0 in Q4 2015, up 62.97% YoY from $37328.0 in Q4 2014, and up 62.97% on a QoQ basis from $37328.0 in Q4 2014.
Powered by 
Analysis
Avalo Therapeutics (AVTX) Accumulated Depreciation (2014 - 2015) Analysis & Trends
Avalo Therapeutics (AVTX) has 2 years of Accumulated Depreciation data on file, last reported at $60835.0 in Q4 2015.
- Quarterly Accumulated Depreciation rose 62.97% year-over-year to $60835.0 in Q4 2015, while the trailing twelve-month figure through Dec 2015 was $60835.0 (up 62.97% YoY) and the FY2015 annual result came in at $60835.0, up 62.97% from the prior year.
- Accumulated Depreciation improved to $60835.0 in Q4 2015, from $37328.0 in the prior quarter.
- In the past five years, Accumulated Depreciation ranged from a high of $60835.0 in Q4 2015 to a low of $37328.0 in Q4 2014.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Avalo Therapeutics | 843.26 Mn | 843.26 Mn | - |